Key Insights

Highlights

Success Rate

84% trial completion

Published Results

77 trials with published results (12%)

Research Maturity

295 completed trials (47% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

9.2%

58 terminated out of 633 trials

Success Rate

83.6%

-2.9% vs benchmark

Late-Stage Pipeline

10%

66 trials in Phase 3/4

Results Transparency

26%

77 of 295 completed with results

Key Signals

77 with results84% success58 terminated

Data Visualizations

Phase Distribution

488Total
Not Applicable (205)
Early P 1 (3)
P 1 (85)
P 2 (129)
P 3 (50)
P 4 (16)

Trial Status

Completed295
Unknown138
Recruiting72
Terminated58
Not Yet Recruiting29
Active Not Recruiting24

Trial Success Rate

83.6%

Benchmark: 86.5%

Based on 295 completed trials

Clinical Trials (633)

Showing 20 of 20 trials
NCT03935282Not ApplicableCompleted

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

NCT05358249Phase 1Active Not Recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT06663319Phase 1RecruitingPrimary

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06750094Phase 3RecruitingPrimary

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT07107230Phase 1RecruitingPrimary

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

NCT07523035Not Yet RecruitingPrimary

Colorectal Adenoma Cohort

NCT06791395Completed

Real-time AI-assisted Endocyroscopy for the Diagnosis of Colorectal Lesions

NCT06662786Phase 3RecruitingPrimary

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT07517848Not ApplicableCompleted

Comparison of the Left-Lateral Horizontal and Supine Positions for Colonoscopy Intervention: A Randomized Controlled Study

NCT04222413Phase 1Recruiting

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT07222800Phase 3Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT01915225RecruitingPrimary

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

NCT01349881Phase 3Active Not RecruitingPrimary

S0820, Adenoma and Second Primary Prevention Trial

NCT02343601Phase 3Completed

Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery

NCT03485209Phase 2Active Not RecruitingPrimary

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT07496528Not ApplicableNot Yet RecruitingPrimary

Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection

NCT02484404Phase 1Active Not RecruitingPrimary

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

NCT04008797Phase 1Active Not Recruiting

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT07213791Phase 1Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT07089771Not ApplicableNot Yet Recruiting

Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy

Scroll to load more

Research Network

Activity Timeline